Dublin, July 17, 2024 (GLOBE NEWSWIRE) -- The "Chagas disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Chagas disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Chagas disease R&D. The therapies under development are focused on novel approaches to treat/improve Chagas disease.
Chagas disease Emerging Drugs Chapters
This segment of the Chagas disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chagas disease Emerging Drugs
Fosravuconazole: Seren Pharmaceuticals Fosravuconazole is a new oral antifungal component developed by Eisai. In 2010, Eisai concluded a license agreement with Seren Pharma, granting them exclusive rights to develop, commercialize, and sublicense the agent in Japan. Fosravuconazole is a prodrug that improves the solubility and bioavailability of ravuconazole, the main active ingredient. When administered to humans, it is rapidly converted to ravuconazole. Ravuconazole demonstrates antifungal activity by inhibiting ergosterol biosynthesis, a membrane component of fungal cells. The drug is in Phase II stage of development for the treatmen of patients with Chagas Disease.
Chagas disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chagas disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chagas disease drugs.
Chagas disease: Therapeutic Assessment
This segment of the report provides insights about the different Chagas disease drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Chagas disease
There are approx. 5+ key companies which are developing the therapies for Chagas disease. The companies which have their Chagas disease drug candidates in the most advanced stage, i.e. Phase II include, Seren Pharmaceuticals.
Key Questions
- How many companies are developing Chagas disease drugs?
- How many Chagas disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chagas disease?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chagas disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chagas disease and their status?
- What are the key designations that have been granted to the emerging drugs?
Companies
- Mitsubishi Tanabe Pharma Corporation
- Eisai Co Ltd
- Selva Therapeutics
- ConserV Bioscience
- Seren Pharmaceuticals
- 7 Hills Pharma
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Chagas disease Report Insights
- Chagas disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Chagas disease Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/z7core
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
